electroCore (ECOR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Sep, 2026Opening remarks and agenda
Chairman welcomed attendees and introduced directors, officers, legal counsel, auditors, and election inspector.
Provided instructions for technical support and outlined the meeting agenda, including voting procedures.
Board and executive committee updates
Introduced current board members and executive officers, including interim President/CFO and COO.
Shareholder proposals
No shareholder proposals were received by the required deadline; none were considered at the meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from electroCore
- Bioelectronic medicine firm posts strong revenue growth and expands FDA-cleared product reach.ECOR
Corporate presentation - Q2 2026 sales up 28%, net loss narrows, but cash burn raises going concern risks.ECORQ2 2026
- Board recommends voting for directors, auditor ratification, and executive pay at the 2026 virtual meeting.ECORProxy filing
- Rapid growth, expanding markets, and platform innovation drive strong financial outlook.ECORIAccess Alpha Virtual Best Ideas Summer Investment Conference 2026
- Q1 2026 revenue up 43% to $9.6M, with improved margins but ongoing net loss and liquidity risks.ECORQ1 2026
- Q3 revenue up 45% year-over-year, net loss narrows, and cash position strengthens.ECORQ3 2024
- Q2 sales hit $6.1M, margin rose to 86%, and $9M was raised, led by VA/DoD and Truvaga growth.ECORQ2 2024
- Q1 2025 revenue up 23% to $6.7M; NeuroMetrix acquired; gross margin 85%; $30M FY outlook.ECORQ1 2025
- 2024 revenue up 57% to $25.2M, gross margin 85%, and net loss narrowed by 37% to $11.9M.ECORQ4 2024